Using genomic scars to select immunotherapy beneficiaries in advanced non-small cell lung cancer von Donker, H. C., van Es, B., Tamminga, M., Lunter, G. A., van Kempen, L. C. L. T., Schuuring, E., Hiltermann, T. J. N., Groen, H. J. M.

Volltext

Treatment goals and changes over time in older patients with non-curable cancer von Stegmann, M. E., Brandenbarg, D., Reyners, A. K. L., van Geffen, W. H., Hiltermann, T. J. N., Berendsen, A. J.

Volltext

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression von van der Wekken, A J, Kuiper, J L, Saber, A, Terpstra, M M, Wei, J, Hiltermann, T J N, Thunnissen, E, Heideman, D A M, Timens, W, Schuuring, E, Kok, K, Smit, E F, van den Berg, A, Groen, H J M

Volltext

The association of nutritional and inflammatory biomarkers with overall survival in patients with non‐small‐cell lung cancer treated with immune checkpoint inhibitors von Horstman, I. M., Vinke, P. C., Suazo‐Zepeda, E., Hiltermann, T. J. N., Heuvelmans, M. A., Corpeleijn, E., Bock, G. H.

Volltext

Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis von Suazo-Zepeda, E., Bokern, M., Vinke, P. C., Hiltermann, T. J. N., de Bock, G. H., Sidorenkov, G.

Volltext

Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature von van der Wekken, A.J, Saber, A, Hiltermann, T.J.N, Kok, K, van den Berg, A, Groen, H.J.M

Volltext

Circulating tumor cells in small-cell lung cancer: a predictive and prognostic factor von Hiltermann, T.J.N., Pore, M.M., van den Berg, A., Timens, W., Boezen, H.M., Liesker, J.J.W., Schouwink, J.H., Wijnands, W.J.A., Kerner, G.S.M.A., Kruyt, F.A.E., Tissing, H., Tibbe, A.G.J., Terstappen, L.W.M.M., Groen, H.J.M.

Volltext

Correspondence between primary and secondary care about patients with cancer: a Delphi consensus study von Stegmann, M. E., Homburg, T. M., Meijer, J. M., Nuver, J., Havenga, K., Hiltermann, T. J. N., Maduro, J. H., Schuling, J., Brandenbarg, D., Berendsen, A. J.

Volltext

EPAC-lung: pooled analysis of circulating tumour cells in advanced non-small cell lung cancer von Lindsay, C.R., Blackhall, F.H., Carmel, A., Fernandez-Gutierrez, F., Gazzaniga, P., Groen, H.J.M., Hiltermann, T.J.N., Krebs, M.G., Loges, S., López-López, R., Muinelo-Romay, L., Pantel, K., Priest, L., Riethdorf, S., Rossi, E., Terstappen, L., Wikman, H., Soria, J.-C., Farace, F., Renehan, A., Dive, C., Besse, B., Michiels, S.

Volltext

Safety and Efficacy of Extended Interval Dosing for Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer During the COVID-19 Pandemic von Hijmering-Kappelle, L.B.M., Hiltermann, T.J.N, Bensch, F.

Volltext

Quality of life after treatment with immune checkpoint inhibitors for lung cancer; the impact of age von Suazo-Zepeda, E., Vinke, P.C., Heuvelmans, M.A., Sidorenkov, G., Hiltermann, T.J.N., de Bock, G.H.

Volltext

Reliability of panel-based mutational signatures for immune-checkpoint-inhibition efficacy prediction in non-small cell lung cancer von Donker, H.C., Cuppens, K., Froyen, G., Groen, H.J.M., Hiltermann, T.J.N., Maes, B., Schuuring, E., Volders, P.-J., Lunter, G.A., van Es, B.

Volltext

A Randomized Controlled Trial comparing Indwelling Pleural Catheters with Talc Pleurodesis (NVALT-14) von Boshuizen, R.C, vd Noort, V, Burgers, J.A, Herder, G.J.M, Hashemi, S.M.S, Hiltermann, T.J.N, Kunst, P.W, Stigt, J.A, van den Heuvel, M.M

Volltext

Safety and tolerability of stereotactic radiotherapy combined with durvalumab with or without tremelimumab in advanced non-small cell lung cancer, the phase I SICI trial von Kievit, H., Muntinghe-Wagenaar, M.B., Hijmering-Kappelle, L.B.M., Hiddinga, B.I., Ubbels, J.F., Wijsman, R., Slingers, G., de Vries, R., Groen, H.J.M, Kerstjens, H.A.M., van der Wekken, A.J., Hiltermann, T.J.N.

Volltext

Structural distress screening and supportive care for patients with lung cancer on systemic therapy: A randomised controlled trial von Geerse, O.P, Hoekstra-Weebers, J.E.H.M, Stokroos, M.H, Burgerhof, J.G.M, Groen, H.J.M, Kerstjens, H.A.M, Hiltermann, T.J.N

Volltext

Health-related problems in adult cancer survivors: development and validation of the Cancer Survivor Core Set von Geerse, O.P., Wynia, K., Kruijer, M., Schotsman, M.J., Hiltermann, T.J.N., Berendsen, A.J.

Volltext

The distress thermometer as a prognostic tool for one-year survival among patients with lung cancer von Geerse, O.P., Brandenbarg, D., Kerstjens, H.A.M., Berendsen, A.J., Duijts, S.F.A., Burger, H., Holtman, G.A., Hoekstra-Weebers, J.E.H.M., Hiltermann, T.J.N.

Volltext

Copy number alterations assessed at the single-cell level revealed mono- and polyclonal seeding patterns of distant metastasis in a small-cell lung cancer patient von Ferronika, P., van den Bos, H., Taudt, A., Spierings, D.C.J., Saber, A., Hiltermann, T.J.N., Kok, K., Porubsky, D., van der Wekken, A.J., Timens, W., Foijer, F., Colomé-Tatché, M., Groen, H.J.M., Lansdorp, P.M., van den Berg, A.

Volltext

Study protocol for the OPTion randomised controlled trial on the effect of prioritising treatment goals among older patients with cancer in a palliative setting von Stegmann, M.E, Schuling, J, Hiltermann, T.J.N, Reyners, A.K.L, Burger, H, Berger, M.Y, Berendsen, A.J

Volltext

Transient thyrotoxicosis during nivolumab treatment von van Kooten, M J, van den Berg, G, Glaudemans, A W J M, Hiltermann, T J N, Groen, H J M, Rutgers, A, Links, T P

Volltext